Tiziana Life Sciences’ Post

A great and elaborate overview of the challenges and tools/biomarkers for the early detection of PIRA in Multiple Sclerosis in clinical practice! #MS #PIRA #smoldering #neuroinflammation #biomarkers

Putting on a Muscular Dystrophy Association clinic today! In our first case, I find myself thinking about supplementation in late onset #congenital #myopathies. #Nacetylcysteine has been used as a supplement but appears to remain experimental and has not had remarkable supportive evidence in patient populations. #neuromuscular #neurology https://lnkd.in/gkvmrD9i

Eculizumab treatment leads to clinical improvement in adolescents with refractory AchR antibody-positive generalized myasthenia gravis, according to a recent study presented at the 9th Congress of the European Academy of Neurology. This is the case whether or not they were receiving chronic intravenous immunoglobin IVIG at baseline. Learn more about this study from Rare Disease Advisor: https://lnkd.in/eFjcpBfm #MGresearch #MedicalResearch #MyastheniaGravis

In this recent paper in JAMA Neurology, with a significant cohort, amyloid-related tau accumulation was accelerated in ApoE4 carriers at lower amyloid levels, suggesting that ApoE4 may facilitate earlier amyloid-driven tau spreading across connected brain regions. Possible therapeutic implications might be further investigated to determine when best to prevent tau spreading and thus cognitive decline depending on ApoE4 status. https://lnkd.in/eXWWXEY8

A recent study in JAMA Neurology found that fecal microbiota transplantation (FMT) does not provide clinically meaningful improvements for Parkinson's disease (PD). Researchers led by Dr. Filip Scheperjans from Helsinki University Hospital studied 47 PD patients, assigning them randomly to receive FMT or a placebo. After six months, changes in Parkinson's disease symptoms, measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale, showed no significant difference between the groups. The FMT group experienced more gastrointestinal adverse events (16 vs. 1). Surprisingly, the placebo group saw a stronger increase in dopaminergic medication and better motor and nonmotor outcomes. Microbiota changes were more pronounced after FMT but varied by donor, while the placebo group more frequently reversed dysbiosis status. The authors suggest further studies to explore modified FMT approaches, bowel cleansing, and the impact of donor microbiota composition on PD outcomes and medication needs. #neurology #parkinsons #microbiota With the Specialist combines artificial intelligence with a board certified neurologist to enhance neurological care in the primary care setting, bringing the neurology consult to you. #withthespecialist #aiinhealthcare #innovation https://lnkd.in/gHR9wwt5 https://lnkd.in/gExrwg2P

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial

Highly recommended analysis from the ELAN trial -- effect of anticoagulation timing in relation to size of cardioembolic stroke -- check it out at JAMA Neurology

At the 2024 American Academy of Neurology conference, significant findings were unveiled regarding the efficacy and safety of Ocrelizumab in the treatment of multiple sclerosis (MS). Insights from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort revealed sustained low disease activity over four years of Ocrelizumab therapy in treatment-naive patients with high-activity, early-stage relapsing-remitting MS. Moreover, the ENSEMBLE Study showcased promising outcomes of 10 years of Ocrelizumab treatment, demonstrating its enduring efficacy and safety. Additionally, results from the OCARINA II Phase III Study highlighted the effectiveness of subcutaneous administration of Ocrelizumab in Multiple Sclerosis patients. Read more about RRMS treatment options @ https://lnkd.in/gu5sF5Ve #AAN2024 #Ocrelizumab #MultipleSclerosis #NeurologyConference #ENSEMBLEtrial #OCARINAII #MSresearch

According to new research featured at the joint ECTRIMS-ACTRIMS meeting, the Multiple Sclerosis Disease Activity (MSDA) Test is a reliable indicator of recent objective disease activity when used within an academic clinic. Based on these findings, Dr. Andrew Wilner sits down with lead author of the study, Dr. William Kilgo, to discuss how the MSDA can be applied in our real-world clinical practice. https://bit.ly/488lth6 #Neurology #MedEd #MS #MultipleSclerosis

Healio Spotlighted Spherix's research on Leqembi for Alzheimer's treatment. Spherix's results revealed that patient requests are driving demand as well as some clinician optimism in Leqembi’s efficacy.   According to Alissa Algarin, Spherix's Neurology Insights Director, "Few surveyed neurologists considered Leqembi to be a significant medical advance over other historical Alzheimer’s treatments and satisfaction with Leqembi was low compared to Spherix neurology launch benchmarks.”    For more insights, check out the full article here: https://lnkd.in/ejyzAq76   #Neurology #AlzheimersDisease #Healio #Leqembi